This episode explores how real-world evidence (RWE) is changing prostate cancer treatment and decision-making. You’ll learn how RWE complements randomized controlled trials (RCTs) and provides deeper insight into long-term outcomes, adherence, and diverse patient populations.

In this episode, you’ll learn:

• Why RWE is becoming essential in modern prostate cancer care
• How apalutamide compares to enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC)
• What the 23% lower mortality risk with apalutamide means for clinicians and patients
• The strengths and limitations of real-world studies versus RCTs
• How RWE can help personalize treatment and improve shared decision-making
• Why is a rigorous study design critical to maintain RWE credibility
• The future of RWE, including integration with biomarkers and long-term data

Discover how RWE is helping oncologists bridge the gap between clinical trials and real-world patient care.

Blog Link: How Real-World Evidence Is Transforming Prostate Cancer Treatment Decisions

Send us a text

Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.

Author: Dr. CHRISTINA NG VAN TZE

📍 Visit us at oncolifecentre.com
📞 Call: +603-2242-2620
📧 Book a consultation or ask a question — we're here to support your journey.